These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37441903)

  • 1. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study.
    Omori M; Minegishi Y; Uruga H; Fukuizumi A; Isobe K; Izumi S; Koyama R; Bando M; Sugiyama H; Takahashi K; Gemma A; Homma S; Sugiyama Y; Kishi K
    Respir Investig; 2023 Sep; 61(5):625-631. PubMed ID: 37441903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
    Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
    Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias.
    Minegishi Y; Sudoh J; Kuribayasi H; Mizutani H; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
    Lung Cancer; 2011 Jan; 71(1):70-4. PubMed ID: 20493578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
    Minegishi Y; Kuribayashi H; Kitamura K; Mizutani H; Kosaihira S; Okano T; Seike M; Azuma A; Yoshimura A; Kudoh S; Gemma A
    J Thorac Oncol; 2011 Apr; 6(4):801-7. PubMed ID: 21336181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
    Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
    Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
    Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
    Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
    Yamasaki M; Murakami I; Nakano K; Doi M; Kitaguchi S; Kondo T; Sakurai J; Hattori N; Arita KI
    Anticancer Res; 2017 Feb; 37(2):923-928. PubMed ID: 28179353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
    Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y
    Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
    Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
    J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).
    Katakami N; Nagata K; Nakakura A; Okamoto T; Kaneda T; Oki M; Watanabe K; Tokito T; Amano Y; Tamiya M; Morita S; Hatachi Y
    Jpn J Clin Oncol; 2024 Sep; ():. PubMed ID: 39311098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
    Nogami N; Kubo T; Bessho A; Sakugawa M; Ikeo S; Yokoyama T; Seki N; Ochiai R; Fujimoto N; Murakami S; Kaira K; Harada T; Kishino D; Takiguchi Y; Shimokawa T; Kiura K; Yamashita N; Okamoto H
    Jpn J Clin Oncol; 2024 Jul; 54(7):805-812. PubMed ID: 38594880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Argiris A; Lee JW; Stevenson J; Sulecki MG; Hugec V; Choong NW; Saltzman JN; Song W; Hansen RM; Evans TL; Ramalingam SS; Schiller JH
    Ann Oncol; 2017 Dec; 28(12):3037-3043. PubMed ID: 28950351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
    Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
    Ikeda N; Arai R; Soda S; Inoue T; Uchida N; Nakamura Y; Masawa M; Kushima Y; Okutomi H; Takemasa A; Shimizu Y; Niho S
    Thorac Cancer; 2022 May; 13(9):1342-1348. PubMed ID: 35318811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.